News

On 12 September, the signing ceremony of the strategic partnership between Autobio and the Medical Biology Laboratory of Japan (hereinafter referred to as MBL) was held in Autobio In Vitro Diagnostics Industrial Park. The ceremony was attended by Fu Guangyu, Executive Vice President of Autobio, Yuta Ito, Vice President of MBL's Marketing Headquarters, Shinichiro Hayashida, Director of MBL's Japanese Marketing and Sales Department, and other relevant personnel. The two parties will leverage their respective strengths in the field of in vitro diagnostics to pursue comprehensive strategic collaboration in the domain of microbiological mass spectrometry.

Mr. Fu Guangyu delivered a speech on behalf of Autobio. He stated that the strategic cooperation between Autobio and MBL is a reflection of the complementary advantages of both parties, synergistic innovation, and a model of technology and resource sharing. We believe that this cooperation will bring new opportunities and broader development space for both parties. We look forward to working with MBL to meet the challenges and achieve mutual benefit and a win-win situation.

In his speech, Yuta Ito highlighted the significance of the collaboration between MBL and its partner, emphasising the potential for mutual benefit and a win-win situation through a shared corporate philosophy. He outlined how the partnership will facilitate market development, encourage innovation and enhance competitiveness in the industry. Yuta Ito stated that MBL is dedicated to strengthening its alliance with Autobio and anticipates a more comprehensive collaboration in the domain of microbiological testing in the future.

MBL's core activities are the research, development, production and sale of clinical diagnostic and research reagents, with a particular focus on the immunological, molecular and epigenomic fields. MBL is committed to the advancement of accurate and efficient diagnostic technologies. MBL is a leading Japanese company in the field of autoimmune disease diagnostics, with a strong market position and high brand recognition. The company holds over 80% of the Japanese autoimmune disease diagnostic market.

Following the signing ceremony, the two parties engaged in a detailed discussion on the strategic cooperation in the field of microbiological testing.